Emerging Trends in COVID-19 Treatment: Learning from Inflammatory Conditions Associated with Cellular Therapies
Autor: | Patrick J. Hanley, Patricia R. M. Rocco, Rachele Ciccocioppo, Jaap Jan Boelens, Catherine M. Bollard, Vincenzo Bronte, Bruce L. Levine, Daniel J. Weiss, Maria Cancio |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Cancer Research medicine.medical_treatment Hemophagocytic Passive 0302 clinical medicine Adrenal Cortex Hormones Immune Reconstitution Inflammatory Syndrome Global health Immunology and Allergy Killer Cells Genetics(clinical) Viral Hyperimmune response Genetics (clinical) Lymphohistiocytosis Plasmapheresis Cellular Therapy Killer Cells Natural Cytokine release syndrome STAT Transcription Factors Oncology 030220 oncology & carcinogenesis Natural Immunotherapy Coronavirus Infections Cytokine Release Syndrome CRS HLH Secondary Hemophagocytic Lymphohistiocytosis medicine.medical_specialty Immunology Pneumonia Viral Context (language use) Lymphohistiocytosis Hemophagocytic Article 03 medical and health sciences Immune reconstitution inflammatory syndrome medicine Humans Intensive care medicine Cytokine release Pandemics Transplantation business.industry Interleukin-6 SARS-CoV-2 Immunization Passive COVID-19 IRIS Cell Biology Pneumonia medicine.disease COVID-19 Drug Treatment Clinical trial 030104 developmental biology Immunization business Interleukin-1 |
Zdroj: | Cytotherapy |
ISSN: | 1477-2566 1465-3249 |
Popis: | Coronavirus disease 2019 (SARS-CoV2) is an active global health threat for which treatments are desperately being sought. Even though most people infected experience mild to moderate respiratory symptoms and recover with supportive care, certain vulnerable hosts develop severe clinical deterioration. While several drugs are currently being investigated in clinical trials, there are currently no approved treatments or vaccines for COVID-19 and hence there is an unmet need to explore additional therapeutic options. At least three inflammatory disorders or syndromes associated with immune dysfunction have been described in the context of cellular therapy. Specifically, Cytokine Release Syndrome (CRS), Immune Reconstitution Inflammatory Syndrome (IRIS), and Secondary Hemophagocytic Lymphohistiocytosis (sHLH) all have clinical and laboratory characteristics in common with COVID19 and associated therapies that could be worth testing in the context of clinical trials. Here we discuss these diseases, their management, and potential applications of these treatment in the context of COVID-19. We also discuss current cellular therapies that are being evaluated for the treatment of COVID-19 and/or its associated symptoms. |
Databáze: | OpenAIRE |
Externí odkaz: |